$heff's $tation of $tocks & $olid DD

[$heff]

$CLDX..So at the Society of Neuro-Oncology Meeting in November, what we’re expecting to present is the randomized portion, which is Group 1; all the patients, all the 70 patients in the study, and we’ll present response data as well as PFS and probably an early look at survival. And then in the Group 2 setting, we’ll present what we have to-date in that Group 2 arm, and where we are, whether have a PFS survival, and some response rates. (from Q3 Earnings transcript)